GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2010

Forest and Almirall Report Positive Late-Stage Data for COPD Therapy

  • Forest Laboratories and Almirall say that positive results were observed in a Phase III trial with its treatment for chronic obstructive pulmonary disease (COPD). The ACCORD COPD 1 Phase III trial compared inhaled aclidinium bromide therapy (200 micrograms and 400 micrograms BID) with placebo.

    The North American trial involved 561 patients and is the first of three Phase III studies investigating the BID administration of aclidinium in COPD patients. The results showed treatment with both doses of the long-acting, inhaled anticholinergic bronchodilator led to statistically significant improvements in morning trough FEV1 at week 12. Aclidinium bromide therapy also significantly improved peak FEV1, the trial’s secondary endpoint.

    Almirall and Forest are jointly developing aclidinium bromide. Forest licensed U.S. rights to the drug from Almirall, which retains rights to the rest of the world. The companies expect results from the ongoing ACCORD COPD II and ATTAIN Phase III during the second half of 2010 or early 2011.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »